Table 2.
Baseline Characteristics and Endpoints (HIV Infections and Deaths) of Infants in Pooled Analysisa
| BAN |
PEPI |
SWEN |
|||||
|---|---|---|---|---|---|---|---|
| 28 wk NVP | Control | 14 wk NVP | 14 wk NVP/AZT | Control | 6 wk NVP | Control | |
| No. of mother-infant pairs | 816 | 632 | 823 | 833 | 792 | 731 | 769 |
| Baseline characteristics | |||||||
| Maternal age, yb | 25 (22–29) | 26 (22–29) | 25 (23–29) | 25 (23–29) | 25 (22–29) | 24 (22–27) | 24 (21–27) |
| Maternal CD4 count at baseline/enrollmentb | 440 (330.5–594) | 443.5 (335–590) | 431 (311–609) | 447 (334–610) | 442 (330.5–618) | 446 (312–601) | 434 (317–620) |
| Mode of delivery (%) | |||||||
| Vaginal | 93.7 | 91.9 | 96.1 | 96.5 | 96.3 | 83.6 | 81.8 |
| Cesarean | 1.0 | 1.9 | 2.2 | 2.8 | 2.5 | 14.4 | 15.7 |
| Instrumental | 5.3 | 6.2 | 1.6 | 0.6 | 1.0 | 2.0 | 2.5 |
| Infant sex (%) | |||||||
| Male | 50.0 | 51.4 | 49.7 | 49.9 | 54.4 | 48.4 | 55.0 |
| Female | 50.0 | 48.6 | 50.3 | 50.1 | 45.6 | 51.6 | 45.0 |
| Infant birth weight (kg)b | 3.0 (2.7–3.3) | 3.0 (2.7–3.3) | 3.1 (2.8–3.3) | 3.0 (2.8–3.3) | 3.0 (2.8–3.3) | 2.9 (2.6–3.2) | 3.0 (2.6–3.2) |
| Endpoints | |||||||
| HIV-1 infection | 13 | 32 | 26 | 34 | 61 | 39 | 54 |
| Death (in children without confirmed HIV-1 infection) | 9 | 9 | 16 | 18 | 17 | 6 | 13 |
Abbreviations: AZT, zidovudine; BAN, Breastfeeding, Antiretrovirals and Nutrition study; HIV-1, human immunodeficiency virus type 1; NVP, nevirapine; PEPI, Post-Exposure Prophylaxis of the Infant study; SWEN, Six-Week Extended Nevirapine study.
a Mode of delivery missing for 2 infants in BAN and 3 infants in PEPI; birth weight missing for 2 infants in PEPI and 8 infants in SWEN.
b Median (interquartile range).